Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Deutsches Krebsforschungszentrum

Lyer, Stefan

Mollenhauer, Jan

Jan Mollenhauer

Annemarie Poustka

Caroline End

Stephanie Blaich

Gaby Bergmann

Marcus Renner

Stefan Lyer

Rainer Wittig

Floris Bikker

Antoon Ligtenberg

Arie Nieuw-Amerongen

Enno Veerman

Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1 as a diagnostic for diagnosing the susceptibility of an individual to sulphate or phosphate groups, as well as methods for diagnosis, prophylaxis or treatment of diseases caused by an agent which possesses at least one accessible sulphate and/or at least one accessible phosphate group.

Use of DMBT1 for capturing sulphate and phosphate group exposing agents

The present invention relates to a protein containing an SRCR domain, a nucleic acid encoding such a protein and a method to produce same. The invention further relates to the use of the nucleic acid and the protein and antibodies directed against the protein.

Protein containing a scavenger receptor cysteine rich domain

Growing community of inventors

Heidelberg, Germany

Jan Mollenhauer